Industry Standards Group, Align Biopharma, Expands to 23 Members

NEW YORK–(BUSINESS WIRE)– Align
Biopharma^TM, a life sciences industry technology
standards group, today introduced 14 leading biopharma companies and
technology and service providers as new members. In six months since it
was formed, Align Biopharma has become a fast-growing influence in the
industry to create and implement open technology standards. The group
now includes a total of 23 members dedicated to making it easier for
healthcare professionals (HCPs) to connect digitally with life sciences
companies.

“Technology standards will solve a significant business problem across
the industry by helping get information to stakeholders when and where
they need it,” said Ed Kloskowski, VP, head of commercial IT at Shire,
one of Align Biopharma’s newest members. “At Shire, we are focused on
meeting the needs of underserved patient communities. Joining forces in
Align Biopharma to work together to harmonize digital engagement in a
way that will ultimately help patients is one more path to serving our
patient community.”

In addition to life sciences companies as members, Align Biopharma now
includes technology providers, Adobe, Exostar, Gigya, Janrain, and Okta,
and service providers Accenture, Cognizant, Deloitte, and Mavens. These
leading companies are helping to define and review Align Biopharma’s
open technology standards to ensure broad industry adoption.

“Align Biopharma has seen an overwhelming response from across the
industry,” said Henry Levy, president of Align Biopharma. “It’s clear
there is a significant opportunity to improve the digital experience for
healthcare professionals. We’re attracting the best experts that are
shaping the standards to simplify how HCPs get the important treatment
information they need.”

Align Biopharma’s first standard is for identity
management. Expected available in summer 2017, the standard defines
the technical requirements for solutions that provide a single sign-on
service for HCPs. Align Biopharma has also begun development of its
second standard for consent and preference management, which will enable
consistency in how healthcare professionals specify communication
preferences with each life sciences company. Align Biopharma expects to
post its consent and preference management standard for public review
and input later this year.

What New Align Biopharma Members Are Saying:

“Accenture is pleased to be a member of Align Biopharma in the quest to
create technology standards that benefit the entire healthcare community
and accelerate treatments to patients who need them,” said Kevin Julian,
senior managing director, Accenture Life Sciences North America.

“Adobe is pleased to join Align Biopharma,” said Thomas Swanson, head of
industry strategy & marketing, healthcare at Adobe. “Open technology
standards development provides the industry standardization it can rely
upon, enabling digital technology to help transform the healthcare
experience.”

“As life sciences companies focus on digital transformation, technology
standards are important to enable efficient information sharing across
systems and platforms,” said Bhaskar Sambasivan, senior vice president
and global head of life sciences markets at Cognizant. “We look forward
to contributing to this important industry initiative that will make it
easier for life sciences companies to collaborate with healthcare
professionals and help improve patient care.”

“The U.S. healthcare system is complex, but by creating and implementing
new standards, Align Biopharma can help advance digital capabilities for
healthcare professionals,” said David Rosner, principal and digital life
sciences leader, Deloitte Consulting LLP. “These new technology
standards can not only benefit providers, but also patients by offering
quicker access to medical records, and providing doctors more time for
patient care.”

“The benefits of Align Biopharma’s standards will extend beyond
healthcare providers and pharmaceutical companies to patients, providing
them a clear and uniform process to give consent for use of their
healthcare data, while protecting their privacy and securing their
personal information,” said Eyal Magen, chief strategy officer of Gigya.
“Gigya is ready to make a significant contribution to this important
effort.”

“Our excitement around Align Biopharma is rooted in our passion to
innovate and collaborate and share those innovations with the broader
industry,” said Jim Kaskade, CEO of Janrain. “We’re eager to come
together with other leading companies and contribute our learnings and
experiences as part of Align Biopharma. We are committed to not only
advancing the HCP experience, but also improving patients’ experiences
and our client organizations’ experiences.”

“Align Biopharma’s technology standards embody a goal tightly aligned
with Mavens’ mission to combine best-in-class cloud technologies to
build software solutions that connect people to cures and elevate the
global healthcare industry,” said Prasad Kanumury, CEO of Mavens. “We
are excited to be a part of this important work, simplifying the lives
of healthcare professionals, and freeing time to focus on patients.”

“An identity standard for HCPs will pave the way to reducing the number
of accounts and passwords a practitioner must remember, and put their
valuable time where it belongs – with patients, not with password
resets,” said Chuck Fontana, VP of business development at Okta. “As an
Align Biopharma member, we look forward to continuing to help healthcare
providers adopt any technology without sacrificing security or user
experience.”

Additional Information

Connect with Align Biopharma on LinkedIn: linkedin.com/company/align-biopharma
Follow
@alignbiopharma on Twitter: twitter.com/alignbiopharma

About Align Biopharma

Align Biopharma is an industry standards group founded by top global
pharmaceutical companies and Veeva Systems. The group includes more than
20 leading pharmaceutical, technology, service provider companies that
are dedicated to making it faster and easier for healthcare
professionals to connect with the life sciences industry. For more
information, visit AlignBiopharma.org.

Please see www.deloitte.com/us/about
for a detailed description of Deloitte’s legal structure.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170713005358/en/